Ligand ID: P2E


Drugbank ID:
DB00917
(Dinoprostone)


Indication:
For the termination of pregnancy during the second trimester (from the 12th through the 20th gestational week as calculated from the first day of the last normal menstrual period), as well as for evacuation of the uterine contents in the management of missed abortion or intrauterine fetal death up to 28 weeks of gestational age as calculated from the first day of the last normal menstrual period. Also used in the management of nonmetastatic gestational trophoblastic disease (benign hydatidiform mole). Other indications include improving the cervical inducibility (cervical "ripening") in pregnant women at or near term with a medical or obstetrical need for labor induction, and the management of postpartum hemorrhage.

Get human targets for P2E in PDB (known and potential targets)

RESULTS FROM SUB-STRUCTURAL SIMILARITY SEARCHES MAPPED TO LIGAND 'P2E'

Click here for results that match SARS-Cov-2 / COVID-19 structures only
Click here for results that match SARS-related structures only


1) User may click on the DrReposER ID (the second column) to get information on the binding sites and drug molecule.
2) Click View (the second last column) to view matched residues and superposition in the NGL viewer (upper right part).
3) User may also click on the Dock (the last column) to get script for molecular docking in UCSF Chimera through AutoDock Vina.

DrReposER ID / Desc. Hit
PDBID		 Hit
Macromolecule		 Res.
Matches		 View Interface RMSD Seq.
Identity (%)		 HETATM Dock
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_A_P2EA1201_0
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		1uk3 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 12
MET B 276
THR A 285
TYR B 239
THR B 199
SER B 284
1.50A19.58
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_B_P2EB1201_0
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		1uk3 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 12
MET B 276
THR A 285
TYR B 239
THR B 199
SER B 284
1.49A19.58
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_A_P2EA1201_0
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		1wnc E2 GLYCOPROTEIN
(SARSr-CoV)		5 / 12
GLN A 939
THR A 943
VAL A 945
LEU B 944
GLN A 936
1.62A12.65
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_B_P2EB1201_0
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		1wnc E2 GLYCOPROTEIN
(SARSr-CoV)		5 / 12
THR D 922
THR D 921
THR F 923
LEU F 920
GLN D 915
1.78A12.65
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_B_P2EB1201_1
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		1z1i 3C-LIKE PROTEINASE
(SARSr-CoV)		4 / 5
PRO A  39
VAL A  42
GLY A  71
VAL A  36
1.47A19.58
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_B_P2EB1201_1
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		1z1j 3C-LIKE PROTEINASE
(SARSr-CoV)		4 / 5
PRO B1099
VAL B1157
GLY B1124
VAL B1148
1.46A19.58
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_A_P2EA1201_0
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		1z1j 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 12
GLN A  19
VAL A  36
TYR A  37
THR A  35
TRP A  31
1.73A19.58
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_A_P2EA1201_0
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		1zv8 E2 GLYCOPROTEIN
(SARSr-CoV)		5 / 12
GLN A  39
THR A  43
VAL A  45
LEU C  44
GLN A  36
1.48A8.66
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_B_P2EB1201_0
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		1zv8 E2 GLYCOPROTEIN
(SARSr-CoV)		5 / 12
THR C  22
THR C  21
THR A  23
LEU A  20
GLN C  15
1.57A8.66
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_B_P2EB1201_1
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		2a5k 3C-LIKE PEPTIDASE
(SARSr-CoV)		4 / 5
PRO B  99
VAL B 157
GLY B 124
VAL B 148
1.53A19.58
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_A_P2EA1201_0
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		2ajf ACE2
(Homo
sapiens)		5 / 12
GLN A 305
THR A 362
VAL A 364
THR A 294
LEU A 423
1.56A20.41
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_B_P2EB1201_1
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		2alv REPLICASE
POLYPROTEIN 1AB
(SARSr-CoV)		4 / 5
PRO A  99
VAL A 157
GLY A 124
VAL A 148
1.53A19.58
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_A_P2EA1201_0
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		2beq SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 12
THR C 922
THR C 921
THR B 923
LEU B 920
GLN C 915
1.60A6.86
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_B_P2EB1201_0
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		2beq SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 12
THR C 922
THR C 921
THR B 923
LEU B 920
GLN C 915
1.60A6.86
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_A_P2EA1201_0
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		2d2d 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 12
GLN B  19
VAL B  36
TYR B  37
THR B  35
TRP B  31
1.74A20.37
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_B_P2EB1201_1
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		2d2d 3C-LIKE PROTEINASE
(SARSr-CoV)		4 / 5
PRO B  99
VAL B 157
GLY B 124
VAL B 148
1.53A20.37
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_B_P2EB1201_0
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		2dd8 IGG HEAVY CHAIN
(Homo
sapiens)		5 / 12
GLN H   5
THR H  77
THR H  70
SER H   7
GLN H 105
1.78A18.46
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_A_P2EA1201_0
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		2dd8 IGG HEAVY CHAIN
(Homo
sapiens)		5 / 12
THR H 107
THR H 108
VAL H 109
LEU H  82
ARG H  38
1.64A18.46
None
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3WFH_B_P2EB301_1
(MAB FAB H FRAGMENT
MAB FAB L FRAGMENT)		2dd8 IGG HEAVY CHAIN
(Homo
sapiens)		5 / 12
HIS H 200
VAL H 198
PRO H 149
TYR H 176
LEU H 178
1.66A61.19
28.06
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_A_P2EA1201_0
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		2g9t ORF1A POLYPROTEIN
(SARSr-CoV)		5 / 12
GLN G  65
THR G 101
LEU H  45
SER G  67
GLN G  98
1.53A17.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_B_P2EB1201_0
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		2g9t ORF1A POLYPROTEIN
(SARSr-CoV)		5 / 12
GLN G  65
THR G 101
LEU H  45
SER G  67
GLN G  98
1.54A17.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_B_P2EB1201_1
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		2op9 REPLICASE
POLYPROTEIN 1AB
(PP1AB, ORF1AB)
3C-LIKE PROTEINASE
(3CL-PRO, 3CLP)
(SARSr-CoV)		4 / 5
PRO B  99
VAL B 157
GLY B 124
VAL B 148
1.51A19.39
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_B_P2EB1201_1
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		2q6g REPLICASE
POLYPROTEIN 1AB
(SARS-COV
BJ01)		4 / 5
PRO A  99
VAL A 157
GLY A 124
VAL A 148
1.52A19.58
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_A_P2EA1201_0
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		2qcy 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 12
GLN A  19
VAL A  36
TYR A  37
THR A  35
TRP A  31
1.72A19.58
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_A_P2EA1201_0
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		2vj1 MAIN PROTEINASE
(SARSr-CoV)		5 / 12
GLN B  19
VAL B  36
TYR B  37
THR B  35
TRP B  31
1.72A19.58
None
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3WFH_B_P2EB301_1
(MAB FAB H FRAGMENT
MAB FAB L FRAGMENT)		3bgf F26G19 FAB
(Mus
musculus)		5 / 12
HIS H 201
VAL H 199
PRO H 151
GLU H 150
LEU H 179
1.75A72.73
25.64
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_B_P2EB1201_1
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		3e91 3C-LIKE PROTEINASE
(SARSr-CoV)		4 / 5
PRO A  99
VAL A 157
GLY A 124
VAL A 148
1.49A20.55
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_A_P2EA1201_0
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		3e91 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 12
GLN B  19
VAL B  36
TYR B  37
THR B  35
TRP B  31
1.70A20.55
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_A_P2EA1201_0
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		3ea9 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 12
GLN A  19
VAL A  36
TYR A  37
THR A  35
TRP A  31
1.73A20.55
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_A_P2EA1201_0
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		3f9e 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 12
GLN A  19
VAL A  36
TYR A  37
THR A  35
TRP A  31
1.66A21.99
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_B_P2EB1201_1
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		3fzd 3C-LIKE PROTEINASE
(SARSr-CoV)		4 / 5
PRO A  99
VAL A 157
GLY A 124
VAL A 148
1.51A19.48
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_A_P2EA1201_0
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		3i6g BETA-2-MICROGLOBULIN
HLA, A-2
(Homo
sapiens)		5 / 12
VAL A  12
THR A  94
LEU B  54
SER A  38
GLN A  43
1.68A21.03
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_B_P2EB1201_0
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		3sci ACE2
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARSr-CoV)		5 / 12
THR B 324
MET B 383
THR F 487
LEU B 351
ARG B 357
1.78A20.32
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_A_P2EA1201_0
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		3sna 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 12
GLN A  19
VAL A  36
TYR A  37
THR A  35
TRP A  31
1.67A19.39
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_B_P2EB1201_1
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		4hi3 3C-LIKE PROTEINASE
(SARSr-CoV)		4 / 5
PRO B  99
VAL B 157
GLY B 124
VAL B 148
1.52A19.35
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_B_P2EB1201_1
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		4mds 3C-LIKE PROTEINASE
(SARSr-CoV)		4 / 5
PRO A  99
VAL A 157
GLY A 124
VAL A 148
1.53A19.58
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_A_P2EA1201_0
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		4tww 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 12
GLN A  19
VAL A  36
TYR A  37
THR A  35
TRP A  31
1.73A19.35
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_B_P2EB1201_1
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		4tww 3C-LIKE PROTEINASE
(SARSr-CoV)		4 / 5
PRO A 252
VAL A 297
GLY A 215
VAL A 303
1.49A19.35
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_B_P2EB1201_0
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		5c8s GUANINE-N7
METHYLTRANSFERASE
NSP10
(SARSr-CoV)		5 / 12
GLN C  65
THR C 101
LEU D  38
SER C  67
GLN C  98
1.50A16.75
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_A_P2EA1201_0
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		5c8s GUANINE-N7
METHYLTRANSFERASE
NSP10
(SARSr-CoV)		5 / 12
GLN C  65
THR C 101
LEU D  38
SER C  67
GLN C  98
1.48A16.75
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_B_P2EB1201_1
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		5rfc 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 5
PRO A  39
VAL A  86
GLY A  79
VAL A  35
1.67A15.66
None
None
K1Y  A 404 ( 3.7A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_B_P2EB1201_1
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		5rfc 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 5
PRO A  99
VAL A 157
GLY A 124
VAL A 148
1.57A15.66
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_A_P2EA1201_0
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		5wrg SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 12
VAL C 718
THR C 716
LEU C 941
SER C 985
GLN C 984
1.75A15.85
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_B_P2EB1201_0
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		5x58 SPIKE GLYCOPROTEIN
(SARS-COV
BJ01)		5 / 12
THR A 980
TYR B 738
THR B 980
ARG A 977
GLN A 737
1.71A15.61
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3WFH_B_P2EB301_1
(MAB FAB H FRAGMENT
MAB FAB L FRAGMENT)		5x59 S PROTEIN
(MERS-CoV)		5 / 12
VAL C 360
TYR A 809
PRO C 658
TYR A 932
LEU A 935
1.53A11.53
10.88
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_A_P2EA1201_0
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		5x5b SPIKE GLYCOPROTEIN
(SARS-COV
BJ01)		5 / 12
MET B 713
VAL B 842
THR B 841
LEU B 749
GLN B 936
1.63A15.61
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_B_P2EB1201_1
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		5x5b SPIKE GLYCOPROTEIN
(SARS-COV
BJ01)		4 / 5
PRO A1035
VAL A1015
GLY A1028
VAL A1047
1.30A15.61
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_A_P2EA1201_1
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		5x5b SPIKE GLYCOPROTEIN
(SARS-COV
BJ01)		4 / 4
PRO A1035
MET A 770
GLY C 682
VAL A 767
1.69A15.61
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_A_P2EA1201_0
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		5x5f S PROTEIN
(MERS-CoV)		5 / 12
GLN C  60
THR B 579
TYR B 577
LEU B 441
GLN C 280
1.66A15.31
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_B_P2EB1201_1
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		5xlr SPIKE GLYCOPROTEIN
(SARSr-CoV)		4 / 5
PRO A1035
VAL A1015
GLY A1028
VAL A1047
1.38A15.85
PRO  A1035 ( 1.1A)
VAL  A1015 ( 0.6A)
GLY  A1028 ( 0.0A)
VAL  A1047 ( 0.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_A_P2EA1201_0
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		5zvm SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 12
GLN C 939
THR C 943
VAL C 945
LEU B 944
GLN C 936
1.69A11.14
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_A_P2EA1201_0
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		6acg SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 12
GLN B 987
VAL B 718
LEU B 948
SER B 985
GLN A 987
1.35A16.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_A_P2EA1201_0
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		6acg ACE2
(Homo
sapiens)		5 / 12
GLN D 305
THR D 362
VAL D 364
THR D 294
LEU D 423
1.67A20.32
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_B_P2EB1201_0
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		6acj SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 12
GLN B 987
LEU B 948
ARG B 982
SER B 985
GLN A 987
1.51A16.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3WFH_B_P2EB301_1
(MAB FAB H FRAGMENT
MAB FAB L FRAGMENT)		6acj ACE2
(Homo
sapiens)		5 / 12
PHE D 274
VAL D 487
TYR D 515
PRO D 451
HIS D 505
1.80A17.64
15.42
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_B_P2EB1201_1
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		6ack SPIKE GLYCOPROTEIN
(SARSr-CoV)		4 / 5
PRO B1035
VAL B1015
GLY B1028
VAL B1047
1.31A16.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_B_P2EB1201_1
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		6crv SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		4 / 5
PRO B1035
VAL B1015
GLY B1028
VAL B1047
1.37A15.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_A_P2EA1201_0
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		6crw SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 12
THR C  31
THR C  67
VAL C  66
TYR C  88
LEU C 182
1.50A16.04
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_B_P2EB1201_1
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		6cs1 SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		4 / 5
PRO C1035
VAL C1015
GLY C1028
VAL C1047
1.17A16.04
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3WFH_B_P2EB301_1
(MAB FAB H FRAGMENT
MAB FAB L FRAGMENT)		6cs2 ACE2
(Homo
sapiens)		5 / 12
PHE D 274
VAL D 487
TYR D 515
PRO D 451
HIS D 505
1.76A17.64
15.57
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_A_P2EA1201_0
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		6cs2 ACE2
(Homo
sapiens)		5 / 12
GLN D 305
THR D 362
VAL D 364
THR D 294
LEU D 423
1.64A20.32
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_B_P2EB1201_0
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		6cs2 SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 12
GLN B 987
LEU B 948
ARG B 982
SER B 985
GLN B 984
1.72A16.04
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_A_P2EA1201_0
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		6iex MHC CLASS I ANTIGEN
(Homo
sapiens)		5 / 12
THR A 187
VAL A 261
THR A 216
LEU A 230
GLN A 242
1.71A21.24
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_B_P2EB1201_1
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		6lze VIRAL PROTEASE
(SARS-CoV-2)		4 / 5
PRO A  99
VAL A 157
GLY A 124
VAL A 148
1.58A20.79
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_B_P2EB1201_1
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		6lze VIRAL PROTEASE
(SARS-CoV-2)		4 / 5
PRO A  39
VAL A  86
GLY A  79
VAL A  35
1.67A20.79
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_B_P2EB1201_1
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		6m0k VIRAL PROTEASE
(SARS-CoV-2)		4 / 5
PRO A  99
VAL A 157
GLY A 124
VAL A 148
1.58A20.79
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_B_P2EB1201_1
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		6m0k VIRAL PROTEASE
(SARS-CoV-2)		4 / 5
PRO A  39
VAL A  86
GLY A  79
VAL A  35
1.67A20.79
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_B_P2EB1201_1
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 5
PRO A   9
VAL C 125
GLY C  29
VAL C  13
1.66A20.79
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_B_P2EB1201_1
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 5
PRO D  99
VAL D 157
GLY D 124
VAL D 148
1.57A20.79
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_B_P2EB1201_1
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 5
PRO D   9
VAL B 125
GLY B  29
VAL B  13
1.64A20.79
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_B_P2EB1201_1
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 5
PRO C   9
VAL A 125
GLY A  29
VAL A  13
1.61A20.79
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_B_P2EB1201_1
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 5
PRO B   9
VAL D 125
GLY D  29
VAL D  13
1.66A20.79
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_B_P2EB1201_1
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 5
PRO D  39
VAL D  86
GLY D  79
VAL D  35
1.64A20.79
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_B_P2EB1201_1
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 5
PRO C  99
VAL C 157
GLY C 124
VAL C 148
1.57A20.79
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_B_P2EB1201_1
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 5
PRO C  39
VAL C  86
GLY C  79
VAL C  35
1.66A20.79
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_B_P2EB1201_1
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 5
PRO B  39
VAL B  86
GLY B  79
VAL B  35
1.65A20.79
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_B_P2EB1201_1
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 5
PRO B  99
VAL B 157
GLY B 124
VAL B 148
1.62A20.79
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_B_P2EB1201_1
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 5
PRO C   9
VAL A 125
GLY A 146
VAL A  13
1.80A20.79
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_B_P2EB1201_1
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 5
PRO A  99
VAL A 157
GLY A 124
VAL A 148
1.63A20.79
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_B_P2EB1201_1
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 5
PRO A  39
VAL A  86
GLY A  79
VAL A  35
1.66A20.79
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_B_P2EB1201_1
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		6m2q 3CL PROTEASE
(SARS-CoV-2)		4 / 5
PRO A  39
VAL A  86
GLY A  79
VAL A  35
1.68A20.79
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_B_P2EB1201_1
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		6m2q 3CL PROTEASE
(SARS-CoV-2)		4 / 5
PRO A  99
VAL A 157
GLY A 124
VAL A 148
1.58A20.79
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_A_P2EA1201_1
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		6m71 NSP12
(SARS-CoV-2)		4 / 4
PRO A 243
MET A 124
GLY A 214
VAL A 182
1.70A17.81
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_B_P2EB1201_1
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		6m71 NSP12
(SARS-CoV-2)		4 / 5
PRO A 243
VAL A 128
GLY A 214
VAL A 182
1.75A17.81
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_B_P2EB1201_0
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		6nb6 SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 12
THR A 863
THR A 865
MET A1032
THR A 869
TRP A 868
1.70A15.27
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_B_P2EB1201_1
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		6nb7 SPIKE GLYCOPROTEIN
(SARSr-CoV)		4 / 5
PRO B1035
VAL B1015
GLY B1028
VAL B1047
1.39A15.27
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_A_P2EA1201_1
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		6nb7 SPIKE GLYCOPROTEIN
(SARSr-CoV)		4 / 4
PRO A1035
MET A 770
GLY B 682
VAL A 767
1.73A15.27
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_B_P2EB1201_0
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		6nb8 S230 ANTIGEN-BINDING
(FAB) FRAGMENT,
HEAVY CHAIN
S230 ANTIGEN-BINDING
(FAB) FRAGMENT,
LIGHT CHAIN
(Homo
sapiens)		5 / 12
GLN L 165
THR L 183
TYR L 197
LEU L 130
GLN H 185
1.62A19.40
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_B_P2EB1201_0
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		6nb8 S230 ANTIGEN-BINDING
(FAB) FRAGMENT,
HEAVY CHAIN
(Homo
sapiens)		5 / 12
GLN H  13
THR H 130
TYR H 159
LEU H 184
SER H 126
1.76A17.30
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_A_P2EA1201_0
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		6nb8 S230 ANTIGEN-BINDING
(FAB) FRAGMENT,
HEAVY CHAIN
S230 ANTIGEN-BINDING
(FAB) FRAGMENT,
LIGHT CHAIN
(Homo
sapiens)		5 / 12
THR H 122
VAL H 123
LEU H  48
ARG H  38
GLN L  43
1.59A17.30
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_A_P2EA1201_0
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		6nb8 S230 ANTIGEN-BINDING
(FAB) FRAGMENT,
HEAVY CHAIN
S230 ANTIGEN-BINDING
(FAB) FRAGMENT,
LIGHT CHAIN
(Homo
sapiens)		5 / 12
GLN L 165
THR L 183
TYR L 197
LEU L 130
GLN H 185
1.61A19.40
None
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3WFH_B_P2EB301_1
(MAB FAB H FRAGMENT
MAB FAB L FRAGMENT)		6nb8 S230 ANTIGEN-BINDING
(FAB) FRAGMENT,
HEAVY CHAIN
(Homo
sapiens)		5 / 12
VAL H 166
HIS H 214
PRO H 163
GLU H 162
LEU H 192
1.67A50.44
26.86
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_A_P2EA1201_1
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		6nur NSP12
(SARSr-CoV)		4 / 4
PRO A 243
MET A 124
GLY A 214
VAL A 182
1.69A18.41
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_B_P2EB1201_0
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
GLN C1005
LEU C 966
ARG C1000
SER C1003
GLN A1005
1.50A16.95
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_B_P2EB1201_1
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 5
PRO A1053
VAL A1033
GLY A1046
VAL A1065
1.36A16.95
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_A_P2EA1201_0
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
GLN C1005
VAL C 736
LEU C 966
SER C1003
GLN A1005
1.35A16.95
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_B_P2EB1201_1
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		6vww URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 5
PRO B  94
VAL B  85
GLY B  77
VAL B  70
1.48A21.17
None
None
GOL  B 403 (-4.0A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_B_P2EB1201_1
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		6vxx SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 5
PRO C1053
VAL C1033
GLY C1046
VAL C1065
1.39A16.00
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_B_P2EB1201_0
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		6vxx SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
GLN C1005
THR C 734
LEU C 858
SER C1003
GLN C1002
1.79A16.00
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_B_P2EB1201_1
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		6vyb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 5
PRO C1053
VAL C1033
GLY C1046
VAL C1065
1.44A16.00
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_B_P2EB1201_0
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		6vyb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
GLN B1005
THR B 734
LEU B 858
SER B1003
GLN B1002
1.76A16.00
None
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3WFH_B_P2EB301_1
(MAB FAB H FRAGMENT
MAB FAB L FRAGMENT)		6w41 CR3022 FAB HEAVY
CHAIN
(Homo
sapiens)		5 / 12
HIS H 200
VAL H 198
PRO H 149
TYR H 176
LEU H 178
1.72A52.50
24.14
None
None
None
None
GOL  L 301 (-4.9A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_A_P2EA1201_0
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		6w41 CR3022 FAB HEAVY
CHAIN
CR3022 FAB LIGHT
CHAIN
(Homo
sapiens)		5 / 12
GLN L 160
THR L 178
TYR L 192
LEU L 125
GLN H 171
1.52A19.78
None
GOL  L 301 (-3.6A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_A_P2EA1201_0
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		6w41 CR3022 FAB HEAVY
CHAIN
CR3022 FAB LIGHT
CHAIN
(Homo
sapiens)		5 / 12
GLN H 171
THR L 178
THR L 180
VAL L 132
TYR L 186
1.66A16.06
None
GOL  L 301 (-3.6A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_B_P2EB1201_0
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		6w41 CR3022 FAB HEAVY
CHAIN
CR3022 FAB LIGHT
CHAIN
(Homo
sapiens)		5 / 12
GLN L 160
THR L 178
TYR L 192
LEU L 125
GLN H 171
1.52A19.78
None
GOL  L 301 (-3.6A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_B_P2EB1201_1
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		6w41 CR3022 FAB HEAVY
CHAIN
CR3022 FAB LIGHT
CHAIN
(Homo
sapiens)		4 / 5
PRO H 167
VAL L 163
GLY H 162
VAL H 181
1.57A16.06
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_A_P2EA1201_1
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		6w41 CR3022 FAB HEAVY
CHAIN
CR3022 FAB LIGHT
CHAIN
(Homo
sapiens)		4 / 4
PRO L  95
MET H 100
GLY H  94
VAL H  37
1.25A19.78
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_B_P2EB1201_1
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		6w41 CR3022 FAB HEAVY
CHAIN
(Homo
sapiens)		4 / 5
PRO H 149
GLY H 139
TRP H 154
VAL H 198
1.73A16.06
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_B_P2EB1201_1
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		6w63 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 5
PRO A  39
VAL A  86
GLY A  79
VAL A  35
1.67A20.79
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_B_P2EB1201_1
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		6w63 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 5
PRO A  99
VAL A 157
GLY A 124
VAL A 148
1.56A20.79
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_A_P2EA1201_0
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		5 / 12
THR C 115
TYR B 268
LEU C 289
SER C 103
GLN C 121
1.60A20.61
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_B_P2EB1201_0
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		5 / 12
THR C 115
TYR B 268
LEU C 289
SER C 103
GLN C 121
1.61A20.61
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_B_P2EB1201_0
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		5 / 12
THR B 115
TYR A 268
LEU B 289
SER B 103
GLN B 121
1.59A20.61
 CL  B 502 ( 4.9A)
None
None
CL  B 502 ( 4.4A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_A_P2EA1201_0
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		5 / 12
THR A 311
THR A 312
TYR A 213
ARG A 183
GLN A 196
1.73A20.61
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_A_P2EA1201_0
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		5 / 12
THR B 115
TYR A 268
LEU B 289
SER B 103
GLN B 121
1.58A20.61
 CL  B 502 ( 4.9A)
None
None
CL  B 502 ( 4.4A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_B_P2EB1201_0
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		5 / 12
THR A 311
THR A 312
TYR A 213
ARG A 183
GLN A 196
1.73A20.61
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_B_P2EB1201_1
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 5
PRO A  94
VAL A  85
GLY A  77
VAL A  70
1.50A20.47
None
None
EDO  A 406 ( 3.9A)
EDO  A 408 (-4.0A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_B_P2EB1201_1
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 5
PRO B  94
VAL B  85
GLY B  77
VAL B  70
1.49A20.47
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_B_P2EB1201_1
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		6wnp 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 5
PRO A  39
VAL A  86
GLY A  79
VAL A  35
1.66A20.79
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_B_P2EB1201_1
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		6wnp 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 5
PRO A  99
VAL A 157
GLY A 124
VAL A 148
1.56A20.79
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_B_P2EB1201_1
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		6wqf 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 5
PRO A  39
VAL A  86
GLY A  79
VAL A  35
1.68A20.79
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_B_P2EB1201_1
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		6wqf 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 5
PRO A  99
VAL A 157
GLY A 124
VAL A 148
1.59A20.79
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_B_P2EB1201_1
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		6yb7 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 5
PRO A  99
VAL A 157
GLY A 124
VAL A 148
1.57A16.39
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_B_P2EB1201_1
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		6yb7 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 5
PRO A  39
VAL A  86
GLY A  79
VAL A  35
1.67A16.39
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_B_P2EB1201_1
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		6yla HEAVY CHAIN
(Homo
sapiens)		4 / 5
PRO B 153
GLY B 143
TRP B 158
VAL B 202
1.66A18.69
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_B_P2EB1201_0
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		6yla HEAVY CHAIN
LIGHT CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		5 / 12
THR H   0
TYR H  32
THR E 385
SER L  62
GLN B   1
1.54A18.69
MLI  B 303 (-4.8A)
None
None
MLI  B 303 (-3.3A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_B_P2EB1201_0
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		6yla HEAVY CHAIN
LIGHT CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		5 / 12
THR B   0
TYR B  32
THR A 385
SER C  62
GLN H   1
1.61A18.69
MLI  B 303 (-4.2A)
None
None
MLI  B 303 ( 3.9A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_B_P2EB1201_1
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		6yla HEAVY CHAIN
(Homo
sapiens)		4 / 5
PRO H 153
GLY H 143
TRP H 158
VAL H 202
1.68A18.69
MLI  H 305 (-4.1A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_A_P2EA1201_0
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		6yla HEAVY CHAIN
LIGHT CHAIN
(Homo
sapiens)		5 / 12
GLN C 166
THR C 184
TYR C 198
LEU C 131
GLN B 175
1.49A20.54
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_B_P2EB1201_0
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		6yla HEAVY CHAIN
LIGHT CHAIN
(Homo
sapiens)		5 / 12
GLN C 166
THR C 184
TYR C 198
LEU C 131
GLN B 175
1.50A20.54
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_A_P2EA1201_0
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		6yla HEAVY CHAIN
LIGHT CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		5 / 12
THR B   0
TYR B  32
THR A 385
SER C  62
GLN H   1
1.62A18.69
MLI  B 303 (-4.2A)
None
None
MLI  B 303 ( 3.9A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_A_P2EA1201_0
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		6yla HEAVY CHAIN
LIGHT CHAIN
(Homo
sapiens)		5 / 12
GLN B 175
THR C 184
THR C 186
VAL C 138
TYR C 192
1.65A18.69
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_A_P2EA1201_0
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		6yla HEAVY CHAIN
LIGHT CHAIN
(Homo
sapiens)		5 / 12
GLN L 166
THR L 184
TYR L 198
LEU L 131
GLN H 175
1.56A20.54
MLI  H 304 ( 4.8A)
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_A_P2EA1201_1
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		6yla HEAVY CHAIN
LIGHT CHAIN
(Homo
sapiens)		4 / 4
PRO C 101
MET B 106
GLY B  98
VAL B  37
1.30A20.54
None
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3WFH_B_P2EB301_1
(MAB FAB H FRAGMENT
MAB FAB L FRAGMENT)		6yla HEAVY CHAIN
(Homo
sapiens)		5 / 12
HIS H 204
VAL H 202
PRO H 153
GLU H 152
LEU H 182
1.72A55.66
30.61
None
None
MLI  H 305 (-4.1A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_B_P2EB1201_0
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		6yla HEAVY CHAIN
LIGHT CHAIN
(Homo
sapiens)		5 / 12
GLN L 166
THR L 184
TYR L 198
LEU L 131
GLN H 175
1.57A20.54
MLI  H 304 ( 4.8A)
None
None
None
None
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3WFH_B_P2EB301_1
(MAB FAB H FRAGMENT
MAB FAB L FRAGMENT)		6yla HEAVY CHAIN
(Homo
sapiens)		5 / 12
VAL B 156
HIS B 204
PRO B 153
GLU B 152
LEU B 182
1.79A55.66
30.61
None
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3WFH_B_P2EB301_1
(MAB FAB H FRAGMENT
MAB FAB L FRAGMENT)		6yla HEAVY CHAIN
(Homo
sapiens)		5 / 12
HIS H 204
VAL H 202
PRO H 153
TYR H 180
LEU H 182
1.74A55.66
30.61
None
None
MLI  H 305 (-4.1A)
None
None
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3WFH_B_P2EB301_1
(MAB FAB H FRAGMENT
MAB FAB L FRAGMENT)		6yla HEAVY CHAIN
(Homo
sapiens)		5 / 12
HIS B 204
VAL B 202
PRO B 153
TYR B 180
LEU B 182
1.70A55.66
30.61
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_A_P2EA1201_0
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		6yla HEAVY CHAIN
(Homo
sapiens)		5 / 12
THR B   9
THR B 114
VAL B 115
LEU B  81
GLN H 111
1.43A18.69
MLI  B 304 (-4.0A)
MLI  B 304 (-3.3A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_A_P2EA1201_0
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		6yla HEAVY CHAIN
(Homo
sapiens)		5 / 12
GLN H 111
THR H   9
THR H 114
VAL H 115
LEU H  81
1.79A18.69
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_A_P2EA1201_0
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		6yla HEAVY CHAIN
LIGHT CHAIN
(Homo
sapiens)		5 / 12
GLN H 175
THR L 184
THR L 186
VAL L 138
TYR L 192
1.64A18.69
None
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3WFH_B_P2EB301_1
(MAB FAB H FRAGMENT
MAB FAB L FRAGMENT)		6yla HEAVY CHAIN
(Homo
sapiens)		5 / 12
VAL H 156
HIS H 204
PRO H 153
GLU H 152
LEU H 182
1.78A55.66
30.61
None
None
MLI  H 305 (-4.1A)
None
None
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3WFH_B_P2EB301_1
(MAB FAB H FRAGMENT
MAB FAB L FRAGMENT)		6yla HEAVY CHAIN
(Homo
sapiens)		5 / 12
HIS B 204
VAL B 202
PRO B 153
GLU B 152
LEU B 182
1.76A55.66
30.61
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_A_P2EA1201_0
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		6yla HEAVY CHAIN
LIGHT CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		5 / 12
THR H   0
TYR H  32
THR E 385
SER L  62
GLN B   1
1.55A18.69
MLI  B 303 (-4.8A)
None
None
MLI  B 303 (-3.3A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_A_P2EA1201_0
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		6yla HEAVY CHAIN
(Homo
sapiens)		5 / 12
THR H   9
THR H 114
VAL H 115
LEU H  81
GLN B 111
1.47A18.69
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_A_P2EA1201_1
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		6yla HEAVY CHAIN
LIGHT CHAIN
(Homo
sapiens)		4 / 4
PRO L 101
MET H 106
GLY H  98
VAL H  37
1.23A20.54
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_B_P2EB1201_1
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		6ym0 HEAVY CHAIN
(Homo
sapiens)		4 / 5
PRO H 130
VAL H 215
GLY H 166
VAL H 185
1.78A18.75
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_A_P2EA1201_0
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		6ym0 HEAVY CHAIN
LIGHT CHAIN
(Homo
sapiens)		5 / 12
GLN H 175
THR L 184
THR L 186
VAL L 138
TYR L 192
1.64A18.75
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_B_P2EB1201_1
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		6ym0 HEAVY CHAIN
LIGHT CHAIN
(Homo
sapiens)		4 / 5
PRO H 171
VAL L 169
GLY H 166
VAL H 185
1.62A18.75
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_A_P2EA1201_0
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		6ym0 HEAVY CHAIN
LIGHT CHAIN
(Homo
sapiens)		5 / 12
GLN L 166
THR L 184
TYR L 198
LEU L 131
GLN H 175
1.48A20.54
None
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3WFH_B_P2EB301_1
(MAB FAB H FRAGMENT
MAB FAB L FRAGMENT)		6ym0 HEAVY CHAIN
(Homo
sapiens)		5 / 12
HIS H 204
VAL H 202
PRO H 153
GLU H 152
LEU H 182
1.75A55.91
29.55
None
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3WFH_B_P2EB301_1
(MAB FAB H FRAGMENT
MAB FAB L FRAGMENT)		6ym0 HEAVY CHAIN
(Homo
sapiens)		5 / 12
VAL H 156
HIS H 204
PRO H 153
GLU H 152
LEU H 182
1.76A55.91
29.55
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_A_P2EA1201_1
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		6ym0 HEAVY CHAIN
LIGHT CHAIN
(Homo
sapiens)		4 / 4
PRO L 101
MET H 106
GLY H  98
VAL H  37
1.27A20.54
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_A_P2EA1201_0
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		6ym0 HEAVY CHAIN
(Homo
sapiens)		5 / 12
GLN H 111
THR H   9
THR H 114
VAL H 115
LEU H  81
1.75A18.75
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_B_P2EB1201_1
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		6ym0 HEAVY CHAIN
(Homo
sapiens)		4 / 5
PRO H 153
GLY H 143
TRP H 158
VAL H 202
1.72A18.75
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_B_P2EB1201_0
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		6ym0 HEAVY CHAIN
LIGHT CHAIN
(Homo
sapiens)		5 / 12
GLN L 166
THR L 184
TYR L 198
LEU L 131
GLN H 175
1.49A20.54
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_B_P2EB1201_1
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		6ynq REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 5
PRO A  99
VAL A 157
GLY A 124
VAL A 148
1.60A21.21
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_B_P2EB1201_1
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		6ynq REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 5
PRO A  39
VAL A  86
GLY A  79
VAL A  35
1.67A21.21
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_A_P2EA1201_0
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		6yor IGG H CHAIN
IGG L CHAIN
(Homo
sapiens)		5 / 12
GLN C 166
THR C 184
TYR C 198
LEU C 131
GLN B 175
1.57A20.54
None
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3WFH_B_P2EB301_1
(MAB FAB H FRAGMENT
MAB FAB L FRAGMENT)		6yor IGG H CHAIN
(Homo
sapiens)		5 / 12
VAL H 156
HIS H 204
PRO H 153
GLU H 152
LEU H 182
1.78A55.66
30.61
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_B_P2EB1201_1
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		6yor IGG H CHAIN
(Homo
sapiens)		4 / 5
PRO H 153
GLY H 143
TRP H 158
VAL H 202
1.67A18.69
None
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3WFH_B_P2EB301_1
(MAB FAB H FRAGMENT
MAB FAB L FRAGMENT)		6yor IGG H CHAIN
(Homo
sapiens)		5 / 12
HIS H 204
VAL H 202
PRO H 153
GLU H 152
LEU H 182
1.73A55.66
30.61
None
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3WFH_B_P2EB301_1
(MAB FAB H FRAGMENT
MAB FAB L FRAGMENT)		6yor IGG H CHAIN
(Homo
sapiens)		5 / 12
HIS B 204
VAL B 202
PRO B 153
TYR B 180
LEU B 182
1.74A55.66
30.61
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_A_P2EA1201_0
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		6yor IGG H CHAIN
IGG L CHAIN
(Homo
sapiens)		5 / 12
GLN B 175
THR C 184
THR C 186
VAL C 138
TYR C 192
1.65A18.69
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_A_P2EA1201_0
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		6yor IGG H CHAIN
IGG L CHAIN
(Homo
sapiens)		5 / 12
GLN H 175
THR L 184
THR L 186
VAL L 138
TYR L 192
1.65A18.69
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_A_P2EA1201_0
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		6yor IGG H CHAIN
IGG L CHAIN
(Homo
sapiens)		5 / 12
GLN L 166
THR L 184
TYR L 198
LEU L 131
GLN H 175
1.56A20.54
None
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3WFH_B_P2EB301_1
(MAB FAB H FRAGMENT
MAB FAB L FRAGMENT)		6yor IGG H CHAIN
(Homo
sapiens)		5 / 12
VAL B 156
HIS B 204
PRO B 153
GLU B 152
LEU B 182
1.78A55.66
30.61
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_B_P2EB1201_0
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		6yor IGG H CHAIN
IGG L CHAIN
(Homo
sapiens)		5 / 12
GLN L 166
THR L 184
TYR L 198
LEU L 131
GLN H 175
1.57A20.54
None
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3WFH_B_P2EB301_1
(MAB FAB H FRAGMENT
MAB FAB L FRAGMENT)		6yor IGG H CHAIN
(Homo
sapiens)		5 / 12
HIS B 204
VAL B 202
PRO B 153
GLU B 152
LEU B 182
1.72A55.66
30.61
None
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3WFH_B_P2EB301_1
(MAB FAB H FRAGMENT
MAB FAB L FRAGMENT)		6yor IGG H CHAIN
(Homo
sapiens)		5 / 12
HIS H 204
VAL H 202
PRO H 153
TYR H 180
LEU H 182
1.74A55.66
30.61
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_A_P2EA1201_0
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		6yor IGG H CHAIN
(Homo
sapiens)		5 / 12
GLN H 111
THR H   9
THR H 114
VAL H 115
LEU H  81
1.78A18.69
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_B_P2EB1201_1
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		6yor IGG H CHAIN
(Homo
sapiens)		4 / 5
PRO B 153
GLY B 143
TRP B 158
VAL B 202
1.69A18.69
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_A_P2EA1201_1
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		6yor IGG H CHAIN
IGG L CHAIN
(Homo
sapiens)		4 / 4
PRO L 101
MET H 106
GLY H  98
VAL H  37
1.25A20.54
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_A_P2EA1201_0
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		6yor IGG H CHAIN
(Homo
sapiens)		5 / 12
GLN B 111
THR B   9
THR B 114
VAL B 115
LEU B  81
1.78A18.69
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_B_P2EB1201_0
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		6yor IGG H CHAIN
IGG L CHAIN
(Homo
sapiens)		5 / 12
GLN C 166
THR C 184
TYR C 198
LEU C 131
GLN B 175
1.58A20.54
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_A_P2EA1201_1
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		6yor IGG H CHAIN
IGG L CHAIN
(Homo
sapiens)		4 / 4
PRO C 101
MET B 106
GLY B  98
VAL B  37
1.22A20.54
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_B_P2EB1201_1
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		6yt8 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 5
PRO A  39
VAL A  86
GLY A  79
VAL A  35
1.65A21.21
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_B_P2EB1201_1
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		6yt8 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 5
PRO A  99
VAL A 157
GLY A 124
VAL A 148
1.62A21.21
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_B_P2EB1201_1
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		7bqy MAIN PROTEASE
(SARS-CoV-2)		4 / 5
PRO A  99
VAL A 157
GLY A 124
VAL A 148
1.56A20.79
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_B_P2EB1201_1
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		7bqy MAIN PROTEASE
(SARS-CoV-2)		4 / 5
PRO A  39
VAL A  86
GLY A  79
VAL A  35
1.65A20.79
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_B_P2EB1201_1
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		7btf NSP12
(SARS-CoV-2)		4 / 5
PRO A 112
VAL A 111
GLY A  13
VAL A  72
1.70A17.81
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_A_P2EA1201_1
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		7btf NSP12
(SARS-CoV-2)		4 / 4
PRO A 243
MET A 124
GLY A 214
VAL A 182
1.73A17.81
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_B_P2EB1201_1
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		7buy VIRUS MAIN PROTEASE
(SARS-CoV-2)		4 / 5
PRO A  39
VAL A  86
GLY A  79
VAL A  35
1.68A20.79
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_B_P2EB1201_1
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		7buy VIRUS MAIN PROTEASE
(SARS-CoV-2)		4 / 5
PRO A  99
VAL A 157
GLY A 124
VAL A 148
1.57A20.79
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_A_P2EA1201_1
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		7bv1 NSP12
(SARS-CoV-2)		4 / 4
PRO A 243
MET A 124
GLY A 214
VAL A 182
1.68A17.23
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_B_P2EB1201_1
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		7bv1 NSP12
(SARS-CoV-2)		4 / 5
PRO A 243
VAL A 128
GLY A 214
VAL A 182
1.77A17.23
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AK3_A_P2EA1201_1
(PROSTAGLANDIN E2
RECEPTOR EP3
SUBTYPE,SOLUBLE
CYTOCHROME B562)		7bv2 NSP12
(SARS-CoV-2)		4 / 4
PRO A 243
MET A 124
GLY A 214
VAL A 182
1.65A17.23
None